Remove Licensing Remove Pharma Companies Remove Sales
article thumbnail

More firms join litigation against Central govt on FDC ban

AuroBlog - Aurous Healthcare Clinical Trials blog

At least seven more pharma companies and a federation of pharma manufacturers have approached the Delhi High Court against the Central Government’s order in the beginning of June prohibiting manufacturing, distribution and sale of 14 fixed dose combinations (FDCs) licensed prior to the year 1988.

article thumbnail

Delhi HC grants 10 days’ time to Govt to file counter affidavit on petitions against ban of 14 FDCs

AuroBlog - Aurous Healthcare Clinical Trials blog

The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharma companies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Valneva, LimmaTech ally on quest for first Shigella vaccine

pharmaphorum

Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's (..)

article thumbnail

Lilly adds to pain pipeline with Asahi Kasei licensing deal

pharmaphorum

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The post Lilly adds to pain pipeline with Asahi Kasei licensing deal appeared first on.

article thumbnail

To insource or outsource drug commercialisation? Flexibility is the answer

Pharmaceutical Technology

In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. One interesting trend is the number of small cap companies and first-time launchers commencing this journey. The rate of drug approvals could be on the rise.

Drugs 130
article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales of €117 million last year. Grünenthal will make the purchase in cash upfront, with the final figure dependent on any closing adjustments.

Drugs 92
article thumbnail

Dr Reddy’s jumps on medical cannabis train, buying Nimbus Health

pharmaphorum

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum.

Licensing 119